New Jersey's Atlantic City Aquarium reopens for the first time in 5 years
Reintroducing the newly renovated South Jersey attraction, it's the Atlantic City Aquarium! After closing its doors in March 2020 due to the pandemic, the Atlantic City Aquarium has reopened and is ready to welcome visitors once again!
Atlantic City Mayor Marty Small Sr. joined aquarium staff and city leaders on Monday for an official ribbon cutting outside the building before taking a first look inside with city partners and stakeholders.
According to a release from the city, the new and improved AC Aquarium at Historic Gardner's Basin has more than 100 species, including Groman, a 225-pound Loggerhead Sea Turtle, along with several diamondback turtles, southern and cow nose rays, sea horses, pipe fish, lionfish, horseshoe crabs — just to name a few.
The aquarium also debuted new exhibits, like its "Under the Sea" coloring area, hurricane simulator and photo booth. Come summer 2025, there will also be six hands-on touch tanks with daily feeding shows for visitors to enjoy.
So how did this all come about? Before the South Jersey attraction closed its doors in 2020, grant funding was secured from the NJ Casino Reinvestment Development Authority for necessary capital improvements. However, the much-needed improvements were greater than originally expected and the COVID-19 pandemic's impact on supply chains created delays in the construction schedule.
The aquarium has since implemented new roofing, windows, flooring, decking, bathroom renovations, HVAC replacement, lighting replacements, interior drywall replacement and painting, new doors at several locations, duct work, and electrical and plumbing repairs. The city secured more money for exterior upgrades through the American Rescue Plan so the building could look brand new both inside and out.
The aquarium is now open seven days a week from 10 a.m.-5 p.m.
Ticket prices are available online
.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
an hour ago
- New York Post
UES pol pushes crackdown on NYC ‘broken' emergency contracting system
An Upper East Side councilwoman wants to crack down on the mayor's ability to dole out controversial no-bid contracts after a series of high-profile boondoggles during the migrant and COVID crises. Councilmember Julie Menin is proposing two new bills in the aim to curb financial fiascos tied to such contracts — like the controversial $432 million sweetheart deal with DocGo that had taxpayers footing the bill for uneaten meals and empty migrant shelters. 'It's time for drastic change by reforming the city's excessive emergency procurement practices that lack vital checks and balances,' Menin said. The measures would cap the mayor's emergency contracting powers at 30 days and force quicker audits of the deals. 3 Julie Menin wants to fix the city's 'broken' emergency contract procurement process. Leonardo Munoz Current law allows the mayor to dole out non-competitive contracts lasting up to one year during a declared emergency. Menin said the frantic procurement process squanders billions in taxpayer dollars due to waste and malfeasance. She pointed to the COVID-19 pandemic, when then-Mayor Bill de Blasio extended emergency declarations over 100 times, spending an eye-popping $7 billion on emergency supplies with little oversight. It led to New York City loading up on mountains of the supplies, which became unnecessary when the crisis ended. 3 The de Blasio administration spent billions on non-competitive emergency contracts during the COVID pandemic. RICHARD HARBUS Under one COVID-era contract, the city spent as much as $7.50 per cloth mask, Menin said. When city officials auctioned off $225 million leftover PPE supplies, they only recouped $500,000. 'These are reforms to a broken contracting system which has price gouged our government,' Menin said. Mayor Eric Adams has also faced intense scrutiny over the emergency contracts handed out during the emergency he declared over the influx of migrants arriving to the city. The Adams administration awarded DocGo contracts worth hundreds of millions of dollars — without a bidding process to hear from other firms — to operate migrant shelters, despite the company having little experience on the matter. 3 The Adams administration doled out more than $5 billion in emergency contract during the migrant crisis. Michael Nigro Reports showed the contractor used unlicensed security guards, tossed thousands of uneaten meals and underutilized shelter space — eventually leading to an investigation by the state Attorney General's Office and the termination of the deal. 'The failures surrounding DocGo for a critical service only reinforced the need for reforming our broken emergency procurement process,' Menin said. One of Menin's bills would also mandate public disclosure of subcontractors, with penalties of up to $100,000 for failing to report financial relationships. 'Recent mayoral administrations have shown no appetite for good government contracting practices and it's time for the City Council to advance vital legislation to save taxpayer dollars, be fiscally responsible and root out corruption,' she said.
The Hill
an hour ago
- The Hill
Robby's Radar: Elon Musk should join the Libertarian Party
I have an idea for Elon Musk: join the Libertarian Party! Actually, don't just join it — take it over! Let me explain. Musk and President Trump seem to have entered some kind of détente following their big blowup last week. The world's richest man is no longer tweeting constantly about Trump being on the Epstein client list, or about how he feels betrayed over the big beautiful bill, which will massively increase the deficit despite Republican promises to finally cut government spending. In fact, he's spent the last several days tweeting about the Los Angeles riots and the importance of emerging AI technology. Trump, for his part, is refusing to engage Elon with particular hostility. Trump recently told reporters that he would be keeping the Tesla he bought from Musk, that he would continue using Starlink, Musk's internet service, and that he wished Elon well. I try not to make political predictions, but it actually would not surprise me in the least if Trump and Elon makeup — or at the very least, if the Republican Party maintains a friendly enough connection to Elon so that the tech billionaire remains a financial backer of, say, Vice President JD Vance when he inevitably runs for president. But here's an alternative idea I'd like to plan in Musk's head, as he is currently party shopping. As a Libertarian Party member, and voter, I would be thrilled to welcome Elon into the party — and I suspect I wouldn't be alone. After all, the Libertarian Party is a natural fit for Elon, whose politics mostly seem to align with Rand Paul and Thomas Massie, the two most libertarian members of Congress in the Republican Party. Elon wants low taxes, lower spending, low regulation, and thinks the federal government's priorities should reflect that: Cut the deficit first, get our fiscal house in order, and worry about the other stuff later. He also wants government regulations to be friendly to technological growth, is particularly motivated to prevent censorship on social media, and thinks the federal response to the COVID-19 pandemic was authoritarian. These are all textbook libertarian issues. What's more, the current trajectory of the Libertarian Party makes it ideal for some new leadership. For years, the party has been the nation's third or fourth largest, alongside the Green Party. In the 2016 election, Libertarian nominee Gary Johnson received 4.5 million votes and about 3 percent of the national vote, a record at the time. In 2020, the Libertarian nominee received about 1 percent of the national vote. In both of those elections, it finished ahead of the Green Party. Behind the scenes, however, the party has gone through something for a transformation over the last two cycles. Johnson, the 2016 nominee, was perceived by some within the Libertarian Party as too liberal and mainstream — not based enough to attract contrarians and dissidents to the party. In response, a faction calling itself the Mises Caucus formed and attempted to take control of the party. In 2022, they succeeded. Their strategy was podcast-focused: Find people who listen to Joe Rogan and like-minded independent thinkers and draw them to the Libertarian Party. The strategy had a certain amount of merit. The party ended up flirting with Robert F Kennedy Jr., and found itself having significant audience overlap with him. But eventually, Kennedy made a quasi-endorsement of Trump and essentially withdrew from the presidential race. Meanwhile, at the Libertarian National Convention, delegates bucked the Mises Caucus and picked their least preferred candidate, Chase Oliver. In response, the Mises Caucus leadership barely tolerated the Libertarian candidate, hindering his campaign in numerous ways. The party's chairwoman, Angela McArdle, the highest-ranking Mises Caucus official, subsequently resigned from the party. The new chair is not a member of this faction and is trying to chart a more neutral course and reunite the party, though the Mises Caucus has vowed to retake control. So that's where we are now: The Libertarian Party could use some new people, some new leadership, and probably a new infusion of cash. If Elon Musk really wants to make Republicans sorry that they failed to live up to his expectations and cut government spending — but quite rationally believes that Democrats will never ever, ever do better — he might find he has the most in common with the ticket that gets my vote every year. Robbie Soave is co-host of The Hill's commentary show 'Rising' and a senior editor for Reason Magazine. This column is an edited transcription of his daily commentary.
Yahoo
an hour ago
- Yahoo
AstraZeneca (LSE:AZN) Partners In Quantum Leap For Drug Development Efficiency
AstraZeneca recently entered into a collaborative research initiative with IonQ, AWS, and NVIDIA, focused on quantum computing innovations in healthcare, which may have added weight to the company's 5% price gain over the past month. Additionally, AstraZeneca's series of product announcements and partnerships, including EU approvals and US designations for various drugs, could have bolstered investor confidence. While the overall market experienced a rise amid positive trade talk sentiments and recovering tech stocks, AstraZeneca's sustained focus on advancements in precision medicine and a robust drug pipeline likely supported its recent positive performance. We've spotted 2 weaknesses for AstraZeneca you should be aware of. Uncover 18 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. The recent collaboration between AstraZeneca and leading tech firms like IonQ, AWS, and NVIDIA underscores the company's commitment to leverage advanced technologies for innovation in precision medicine. This could positively impact AstraZeneca's revenue and earnings forecasts, as quantum computing may enhance drug discovery processes, potentially boosting the company's competitive edge. The introduction of approved drugs such as Beyonttra and strategic moves in emerging markets and R&D centers, like in Beijing, could further drive revenue and market share growth. Over the past five years, AstraZeneca's total shareholder return, including dividends, was 46.03%. In contrast, despite recent gains, its one-year share return lagged behind the UK market return of 4.9% and the UK Pharmaceuticals industry decline of 8.9%. This suggests that while AstraZeneca has experienced strong overall long-term performance, recent market conditions have presented challenges. Considering analysts' consensus, the current share price of £107.28 reflects a discount to the fair value price target of £133.57, indicating that the market may underrate AstraZeneca's future potential. If the positive implications of ongoing projects materialize, it might align market expectations with analysts' optimistic forecasts. Investors may look to these innovations and strategic maneuvers as catalysts for substantial growth, supporting the expectations that revenue will grow to $65.3 billion and earnings to $13.5 billion by 2028. Gain insights into AstraZeneca's historical outcomes by reviewing our past performance report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include LSE:AZN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
